SI1725553T1 - Derivati tetrahidropiridoindola - Google Patents

Derivati tetrahidropiridoindola

Info

Publication number: SI1725553T1
Authority: SI; Slovenia
Prior art keywords: tetrahydropyridoindole derivatives; tetrahydropyridoindole; derivatives
Prior art date: 2004-03-11

Application number

SI200530281T

Other languages

English (en)

Inventor

Heinz Fretz

Anja Fecher

Kurt Hilpert

Markus Riederer

Original Assignee

Actelion Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-03-11

Filing date

2005-03-07

Publication date

2008-08-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34961211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1725553(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-03-07 Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd

2008-08-31 Publication of SI1725553T1 publication Critical patent/SI1725553T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Otolaryngology (AREA)
Hematology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Indole Compounds (AREA)

SI200530281T 2004-03-11 2005-03-07 Derivati tetrahidropiridoindola SI1725553T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP2004002493		2004-03-11
EP05715779A EP1725553B1 (en)	2004-03-11	2005-03-07	Tetrahydropyridoindole derivatives
PCT/EP2005/002362 WO2005095397A1 (en)	2004-03-11	2005-03-07	Tetrahydropyridoindole derivatives

Publications (1)

Publication Number	Publication Date
SI1725553T1 true SI1725553T1 (sl)	2008-08-31

Family

ID=34961211

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI200530281T SI1725553T1 (sl)	2004-03-11	2005-03-07	Derivati tetrahidropiridoindola

Country Status (24)

Country	Link
US (2)	US7714132B2 (sl)
EP (1)	EP1725553B1 (sl)
JP (1)	JP4051398B2 (sl)
KR (1)	KR100808742B1 (sl)
CN (1)	CN1930162B (sl)
AR (1)	AR047928A1 (sl)
AT (1)	ATE394399T1 (sl)
AU (1)	AU2005229356B2 (sl)
BR (1)	BRPI0508540B8 (sl)
CA (1)	CA2558509C (sl)
DE (1)	DE602005006539D1 (sl)
DK (1)	DK1725553T3 (sl)
ES (1)	ES2304010T3 (sl)
IL (1)	IL177968A0 (sl)
MY (1)	MY143795A (sl)
NO (1)	NO337996B1 (sl)
NZ (1)	NZ550365A (sl)
PL (1)	PL1725553T3 (sl)
PT (1)	PT1725553E (sl)
RU (1)	RU2387652C2 (sl)
SI (1)	SI1725553T1 (sl)
TW (1)	TWI369356B (sl)
WO (1)	WO2005095397A1 (sl)
ZA (1)	ZA200608446B (sl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1833791T3 (da)	2004-12-27	2011-10-24	Actelion Pharmaceuticals Ltd	2,3,4,9-tetrahydor-1H-carbazolderivater som CRTH2 receptorantagonister
RU2303597C1 (ru) *	2006-05-12	2007-07-27	Иващенко Андрей Александрович	Фармацевтическая композиция, способы ее получения и применения
US9254293B2 (en)	2006-06-16	2016-02-09	The Trustees Of The University Of Pennsylvania	Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH
US20150072963A1 (en) *	2006-06-16	2015-03-12	The Trustees Of The University Of Pennsylvania	Compositions and methods for regulating hair growth
BRPI0715179A2 (pt) *	2006-08-07	2013-06-11	Actelion Pharmaceuticals Ltd	composto, composiÇço farmacÊutica e uso de um composto
WO2008070994A1 (en)	2006-12-14	2008-06-19	Nps Pharmaceuticals, Inc.	Use of d-serine derivatives for the treatment of anxiety disorders
US8153798B2 (en)	2007-03-09	2012-04-10	High Point Pharmaceuticals, Llc	Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors
RU2338745C1 (ru) *	2007-03-21	2008-11-20	Андрей Александрович Иващенко	ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
RU2451019C2 (ru) *	2007-10-10	2012-05-20	КЕМИТЕК, ЭлЭлСи	Гетероциклические соединения в качестве антагонистов crth2 рецептора
RU2544856C2 (ru) *	2008-01-25	2015-03-20	Сергей Олегович Бачурин	НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
HK1150388A1 (en) *	2008-01-25	2011-12-23	Medivation Technologies Inc	New 2,3,4,5-tetrahydro-1h-pyrido[4,3-b]indole compounds and methods of use thereof 2345--1h-[43-b]
US20110112134A1 (en) *	2008-05-16	2011-05-12	Amira Pharmaceuticals, Inc.	Tricyclic Antagonists of Prostaglandin D2 Receptors
WO2010008864A2 (en) *	2008-06-24	2010-01-21	Amira Pharmaceuticals, Inc.	Cycloalkane[b]indole angtagonists of prostaglandin d2 receptors
GB2465062B (en)	2008-11-06	2011-04-13	Amira Pharmaceuticals Inc	Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
DK2401269T3 (da) *	2009-02-24	2014-04-28	Merck Sharp & Dohme	Indolderivater som crth2-receptorantagonister
KR20120046762A (ko) *	2009-07-31	2012-05-10	판미라 파마슈티칼스, 엘엘씨	Ｄｐ2 수용체 길항제의 피부 제형
CA2790139C (en)	2010-03-22	2018-03-13	Actelion Pharmaceuticals Ltd	3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
EP2457900A1 (en)	2010-11-25	2012-05-30	Almirall, S.A.	New pyrazole derivatives having CRTh2 antagonistic behaviour
SI2697223T1 (sl)	2011-04-14	2016-10-28	Actelion Pharmaceuticals Ltd.	Derivati 7-(heteroaril-amino)-6,7,8,9-tetrahidropirido(1,2-A)indol-ocetne kisline in njihova uporaba kot modulatorji prostaglandinskega receptorja D2
UA112667C2 (uk)	2011-12-16	2016-10-10	Атопікс Терапеутікс Лімітед	Комбінація антагоніста crth2 і інгібітору протонного насоса для лікування еозинофільного езофагіту
AP2015008858A0 (en) *	2013-05-28	2015-11-30	Astrazeneca Ab	Chemical compounds
EP3119779B1 (en)	2014-03-17	2018-07-11	Idorsia Pharmaceuticals Ltd	Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
CA2938107A1 (en)	2014-03-18	2015-09-24	Actelion Pharmaceuticals Ltd	Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
US9907786B2 (en)	2014-10-21	2018-03-06	Ions Pharmaceutical S.À R.L.	Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US10092550B2 (en)	2014-10-21	2018-10-09	Ions Pharmaceutical S.À R.L.	Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
WO2016128565A1 (en)	2015-02-13	2016-08-18	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
ES2947824T3 (es)	2015-07-30	2023-08-21	Univ Pennsylvania	Alelos polimórficos de un solo nucleótido del gen DP-2 humano para la detección de la susceptibilidad a la inhibición del crecimiento del cabello por antagonistas de PGD2
KR20180053345A (ko)	2015-09-15	2018-05-21	이도르시아 파마슈티컬스 리미티드	결정질 형태
EP3761960B1 (en) *	2018-03-09	2023-11-22	Kiora Pharmaceuticals GmbH	Ophthalmic formulation
SI3810283T1 (sl)	2018-06-21	2023-10-30	F. Hoffmann-La Roche Ag	Trdne oblike tartratne soli 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropil)azetidin-3-il)amino) fenil)-3-metil-1,3,4,9-tetrahidro-2H-pirido(3,4-b)indol-2-il)-2,2- difluoropropan-1-ola, postopek za njihovo pripravo in metode njihove uporabe pri zdravljenju raka
KR20210008223A (ko)	2019-07-11	2021-01-21	제이투에이치바이오텍 (주)	탈모증의 치료 또는 개선을 위한 화합물 및 이들의 용도
US12129265B2 (en)	2020-07-21	2024-10-29	Ankh Life Sciences Limited	Therapeutic agents and uses thereof
KR20240141133A (ko) *	2023-03-15	2024-09-25	한국과학기술연구원	신규한 피리도인돌 유도체 화합물을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 조성물

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4808608A (en) *	1986-01-23	1989-02-28	Merck & Co., Inc.	Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
US5817756A (en) *	1993-09-09	1998-10-06	Scios Inc.	Pseudo- and non-peptide bradykinin receptor antagonists
WO1995007294A1 (en)	1993-09-09	1995-03-16	Scios Nova Inc.	Pseudo- and non-peptide bradykinin receptor antagonists
TR199701667T2 (xx)	1995-06-21	1999-10-21	Shionogi & Co.,Ltd.	�ift �evrimli amino t�revleri ve bu t�revleri i�eren PGD2 antogonisti.
RU2140417C1 (ru) *	1995-10-17	1999-10-27	Институт физиологически активных веществ РАН	Производные гидрированных пиридо(4,3-b)индолов, способы их получения, фармацевтическая композиция и способ лечения
DE69733271T2 (de)	1996-12-12	2006-01-26	Shionogi & Co., Ltd.	Kondensierte heterocyclische benzolcarbonsäureamid-derivate und diese enthaltende pgd2 antagonisten
KR100433568B1 (ko)	1996-12-13	2004-05-31	시오노기세이야쿠가부시키가이샤	벤조티오펜카르복사미드 유도체 및 이를 함유한 ｐｇｄ2 길항제
DE69925270T2 (de)	1998-06-03	2006-02-23	Shionogi & Co., Ltd.	Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten
ATE315230T1 (de)	1999-08-23	2006-02-15	Bml Inc	Verfahren zum identifizieren von prostaglandin d2 rezeptor modulatoren
US20010047027A1 (en)	2000-04-12	2001-11-29	Marc Labelle	Prostaglandin D2 receptor antagonists
AU2001250206A1 (en)	2000-04-12	2001-10-30	Merck Frosst Canada Ltd	Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists
WO2001094309A1 (fr)	2000-06-02	2001-12-13	Shionogi & Co., Ltd.	Composition medicamenteuse antagoniste pour les recepteurs de pgd2/txa2
US6878522B2 (en)	2000-07-07	2005-04-12	Baiyong Li	Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
US7217725B2 (en) *	2000-09-14	2007-05-15	Allergan, Inc.	Prostaglandin D2 antagonist
WO2002032892A1 (en)	2000-10-17	2002-04-25	Shionogi & Co., Ltd	Process for the preparation of pgd2 antagonist
US6933317B2 (en)	2000-11-01	2005-08-23	Shionogi & Co. Ltd.	PGD2 receptor antagonistic pharmaceutical compositions
FR2821854B1 (fr)	2001-03-09	2004-07-16	Genoway	Cellules et animaux transgeniques d'etude de la polarisation de la reponse immune
EP1395590B1 (en)	2001-05-23	2006-09-27	Merck Frosst Canada & Co.	Dihydropyrrolo¬1,2-a\|indole and tetrahydropyrido¬1,2-a\|indole derivatives as prostaglandin d2 receptor antagonists
US20040185509A1 (en)	2001-07-18	2004-09-23	Francois Gervais	Eosinophil prostaglandin d2 receptor assays
US20040197834A1 (en)	2001-07-20	2004-10-07	Francois Gervais	Method to increase expression of pgd2 receptors and assays for identifying modulators of prostaglandin d2 receptors
AR038136A1 (es)	2002-01-24	2004-12-29	Merck Frosst Canada Inc	Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
SE0200411D0 (sv)	2002-02-05	2002-02-05	Astrazeneca Ab	Novel use
SE0200356D0 (sv)	2002-02-05	2002-02-05	Astrazeneca Ab	Novel use
WO2003097598A1 (fr) *	2002-05-16	2003-11-27	Shionogi & Co., Ltd.	Composé comprenant un antagonisme du récepteur de pdg2
JPWO2003097042A1 (ja)	2002-05-16	2005-09-15	塩野義製薬株式会社	Ｐｇｄ２受容体拮抗剤
GB2388540A (en)	2002-05-17	2003-11-19	Bayer Ag	New use of Ramatroban
TW200307542A (en) *	2002-05-30	2003-12-16	Astrazeneca Ab	Novel compounds
SE0201635D0 (sv)	2002-05-30	2002-05-30	Astrazeneca Ab	Novel compounds
SE0202241D0 (sv)	2002-07-17	2002-07-17	Astrazeneca Ab	Novel Compounds
US7211672B2 (en)	2002-10-04	2007-05-01	Millennium Pharmaceuticals, Inc.	PGD2 receptor antagonists for the treatment of inflammatory diseases
EP1413306A1 (en)	2002-10-21	2004-04-28	Warner-Lambert Company LLC	Tetrahydroquinoline derivatives as CRTH2 antagonists
AU2003269327A1 (en)	2002-10-21	2004-05-04	Warner-Lambert Company Llc	Tetrahydroquinoline derivatives as crth2 antagonists
US7618979B2 (en)	2002-10-30	2009-11-17	Merck Frosst Canada Ltd.	Pyridopyrrolizine and pyridoindolizine derivatives
BR0317591A (pt)	2002-12-20	2005-11-22	Amgen Inc	Composto, sal ou pró-medicamento farmaceuticamente aceitáveis, composição farmacêutica, e, métodos para tratar uma doença ou condição, para modular a função de crth2 e/ou um ou mais outros receptores de pgd2 em uma célula e para modular crth2 e/ou um ou mais outros receptores de pgd2
EP1435356A1 (en)	2003-01-06	2004-07-07	Warner-Lambert Company LLC	Quinoline derivatives as CRTH2 antagonists
WO2004074240A1 (ja)	2003-02-20	2004-09-02	Taisho Pharmaceutical Co. Ltd.	プロスタグランジン誘導体
JPWO2004078719A1 (ja)	2003-03-06	2006-06-08	小野薬品工業株式会社	インドール誘導体化合物およびその化合物を有効成分とする薬剤
SE0301010D0 (sv)	2003-04-07	2003-04-07	Astrazeneca Ab	Novel compounds
SE0301009D0 (sv)	2003-04-07	2003-04-07	Astrazeneca Ab	Novel compounds
DK1471057T3 (da)	2003-04-25	2006-05-15	Actimis Pharmaceuticals Inc	Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2
US20070054951A1 (en)	2003-05-20	2007-03-08	Lianhai Li	Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists
SE0301569D0 (sv)	2003-05-27	2003-05-27	Astrazeneca Ab	Novel compounds
US20070027171A1 (en)	2003-06-12	2007-02-01	Lachance Nicolas	Cycloalkanepyrrolopyridines as dp receptor antagonists
WO2005007094A2 (en)	2003-07-09	2005-01-27	Tularik Inc.	Asthma and allergic inflammation modulators
SE0302232D0 (sv)	2003-08-18	2003-08-18	Astrazeneca Ab	Novel Compounds
SA04250253B1 (ar)	2003-08-21	2009-11-10	استرازينيكا ايه بي	احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
JP4861976B2 (ja)	2004-03-11	2012-01-25	アクテリオンファーマシューティカルズリミテッド	インドール−１−イル酢酸誘導体
MX2007002126A (es)	2004-08-26	2007-09-14	Actelion Pharmaceuticals Ltd	Derivados de acido 2-sulfanil-benzoimidazol-1-il-acetico como antagonistas de crth 2.
DK1833791T3 (da)	2004-12-27	2011-10-24	Actelion Pharmaceuticals Ltd	2,3,4,9-tetrahydor-1H-carbazolderivater som CRTH2 receptorantagonister
BRPI0715179A2 (pt)	2006-08-07	2013-06-11	Actelion Pharmaceuticals Ltd	composto, composiÇço farmacÊutica e uso de um composto

2005
- 2005-03-07 CA CA2558509A patent/CA2558509C/en not_active Expired - Fee Related
- 2005-03-07 SI SI200530281T patent/SI1725553T1/sl unknown
- 2005-03-07 ES ES05715779T patent/ES2304010T3/es active Active
- 2005-03-07 DK DK05715779T patent/DK1725553T3/da active
- 2005-03-07 US US10/598,777 patent/US7714132B2/en not_active Expired - Fee Related
- 2005-03-07 WO PCT/EP2005/002362 patent/WO2005095397A1/en active IP Right Grant
- 2005-03-07 DE DE602005006539T patent/DE602005006539D1/de active Active
- 2005-03-07 CN CN2005800076993A patent/CN1930162B/zh not_active Expired - Fee Related
- 2005-03-07 EP EP05715779A patent/EP1725553B1/en active Active
- 2005-03-07 AU AU2005229356A patent/AU2005229356B2/en not_active Ceased
- 2005-03-07 NZ NZ550365A patent/NZ550365A/en not_active IP Right Cessation
- 2005-03-07 AT AT05715779T patent/ATE394399T1/de active
- 2005-03-07 PL PL05715779T patent/PL1725553T3/pl unknown
- 2005-03-07 RU RU2006135651/04A patent/RU2387652C2/ru not_active IP Right Cessation
- 2005-03-07 PT PT05715779T patent/PT1725553E/pt unknown
- 2005-03-07 BR BRPI0508540A patent/BRPI0508540B8/pt not_active IP Right Cessation
- 2005-03-07 KR KR1020067018133A patent/KR100808742B1/ko active IP Right Grant
- 2005-03-07 JP JP2007501238A patent/JP4051398B2/ja not_active Expired - Fee Related
- 2005-03-09 MY MYPI20050978A patent/MY143795A/en unknown
- 2005-03-11 TW TW094107583A patent/TWI369356B/zh not_active IP Right Cessation
- 2005-03-11 AR ARP050100957A patent/AR047928A1/es active IP Right Grant
2006
- 2006-09-07 IL IL177968A patent/IL177968A0/en active IP Right Grant
- 2006-10-10 ZA ZA200608446A patent/ZA200608446B/en unknown
- 2006-10-10 NO NO20064584A patent/NO337996B1/no not_active IP Right Cessation
2010
- 2010-03-16 US US12/724,946 patent/US20100234396A1/en not_active Abandoned

Also Published As

Publication number	Publication date
MY143795A (en)	2011-07-15
CN1930162A (zh)	2007-03-14
PL1725553T3 (pl)	2008-10-31
ES2304010T3 (es)	2008-09-01
TW200538434A (en)	2005-12-01
PT1725553E (pt)	2008-07-16
WO2005095397A1 (en)	2005-10-13
NO337996B1 (no)	2016-07-18
EP1725553B1 (en)	2008-05-07
BRPI0508540A (pt)	2007-09-18
JP4051398B2 (ja)	2008-02-20
DK1725553T3 (da)	2008-08-18
NO20064584L (no)	2006-10-10
US20100234396A1 (en)	2010-09-16
US7714132B2 (en)	2010-05-11
DE602005006539D1 (de)	2008-06-19
CN1930162B (zh)	2010-06-16
BRPI0508540B8 (pt)	2021-05-25
CA2558509A1 (en)	2005-10-13
KR100808742B1 (ko)	2008-02-29
IL177968A0 (en)	2006-12-31
BRPI0508540B1 (pt)	2019-04-02
AU2005229356A1 (en)	2005-10-13
AU2005229356B2 (en)	2011-06-09
RU2006135651A (ru)	2008-04-20
ZA200608446B (en)	2008-06-25
BRPI0508540A8 (pt)	2017-12-26
ATE394399T1 (de)	2008-05-15
NZ550365A (en)	2010-09-30
AR047928A1 (es)	2006-03-01
JP2007526276A (ja)	2007-09-13
RU2387652C2 (ru)	2010-04-27
KR20070029670A (ko)	2007-03-14
TWI369356B (en)	2012-08-01
US20070191416A1 (en)	2007-08-16
EP1725553A1 (en)	2006-11-29
CA2558509C (en)	2011-11-22

Publication	Publication Date	Title
IL180481A0 (en)	2007-06-03	Aryl-pyridine derivatives
IL177968A0 (en)	2006-12-31	Tetrahydropyridoindole derivatives
ZA200610102B (en)	2008-08-27	Pyrrazolo-pyrimidine derivatives
IL180331A0 (en)	2007-07-04	3-carbamoyl - 2 - pyridone derivative
HUS2000022I1 (hu)	2020-07-28	Tiglien-3-on származékok
EP1878727A4 (en)	2013-11-13	2-AMINOQUINAZOLINE DERIVATIVES
HK1105966A1 (en)	2008-02-29	New 4-benzylidene-piperidin derivatives
IL185674A0 (en)	2008-01-06	1-benzylindole-2-carboxamide derivatives
IL183140A0 (en)	2007-09-20	Substituted benzoquinolizine derivatives
ZA200703172B (en)	2008-08-27	Imidazo-benzodiazepine derivatives
IL177204A0 (en)	2006-12-10	Novel 4-benzimidazol -2-ylpyridazin -3- one derivatives
IL183142A0 (en)	2007-09-20	New pyridothienopyrimidine derivatives
HK1100002A1 (en)	2007-08-31	4-phenyl-pyrimidine-2-carbonitrile derivatives
IL183141A0 (en)	2007-09-20	New pyridothienopyrimidine derivatives
IL182739A0 (en)	2007-07-24	Acylatednonadepsipeptides used as lysobactin derivatives
HK1100775A1 (en)	2007-09-28	4-Amino-5-cyanopyrimidine derivatives
GB0414272D0 (en)	2004-07-28	OsK1 derivatives
IL191138A0 (en)	2008-12-29	Pyrazoloisoquinoline derivatives
IL182001A0 (en)	2007-07-04	2-acylaminothiazole derivatives
GB0511410D0 (en)	2005-07-13	Benzotrizepinone derivatives
GB0422397D0 (en)	2004-11-10	3-Cyano-Quinoline derivatives
GB0405905D0 (en)	2004-04-21	Azaquinazoline derivatives
HUP0402371A2 (en)	2006-09-28	Novel 125-i-labeled amino-quinoline derivatives
GB0500900D0 (en)	2005-02-23	Azaquinazoline derivatives